IL13 and allergic bronchopulmonary aspergillosis: Therefore, tezepelumab can be a suitable agent for the treatment of ABPA, since it binds to and inhibits TSLP, an epithelial cell–derived proinflammatory cytokine implicated in multiple downstream processes including IL‐5, IL‐13 and ILC2 pathways.